KDR and breast carcinoma: Piceatannol was also found to decrease the levels of some pro-angiogenic and pro-lymphangiogenic factors, such as VEGF-A, VEGFR-2, VEGF-C, and LYVE-1, through modulation of NF-κB and STAT3 transcription factors in breast cancer in vivo, and diminished macrophage infiltration in tumor tissue via attenuating the MCP-1 and M-CSF chemoattractants [111].